BR112021013944A8 - Polipeptídeos de interleucina-34 (il-34) mutada e usos dos mesmos em terapias - Google Patents

Polipeptídeos de interleucina-34 (il-34) mutada e usos dos mesmos em terapias

Info

Publication number
BR112021013944A8
BR112021013944A8 BR112021013944A BR112021013944A BR112021013944A8 BR 112021013944 A8 BR112021013944 A8 BR 112021013944A8 BR 112021013944 A BR112021013944 A BR 112021013944A BR 112021013944 A BR112021013944 A BR 112021013944A BR 112021013944 A8 BR112021013944 A8 BR 112021013944A8
Authority
BR
Brazil
Prior art keywords
polypeptides
interleukin
mutated
therapies
demonstrated
Prior art date
Application number
BR112021013944A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112021013944A2 (enrdf_load_html_response
Inventor
Guillonneau Carole
Anegon Ignacio
Mortier Erwan
Quemener Agnès
Original Assignee
Univ Nantes
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nantes, Inst Nat Sante Rech Med filed Critical Univ Nantes
Publication of BR112021013944A2 publication Critical patent/BR112021013944A2/pt
Publication of BR112021013944A8 publication Critical patent/BR112021013944A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2334—Interleukin-34 (IL-34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR112021013944A 2019-01-15 2020-01-15 Polipeptídeos de interleucina-34 (il-34) mutada e usos dos mesmos em terapias BR112021013944A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305046 2019-01-15
PCT/EP2020/050920 WO2020148338A1 (en) 2019-01-15 2020-01-15 Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy

Publications (2)

Publication Number Publication Date
BR112021013944A2 BR112021013944A2 (enrdf_load_html_response) 2021-11-21
BR112021013944A8 true BR112021013944A8 (pt) 2023-02-07

Family

ID=65228484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021013944A BR112021013944A8 (pt) 2019-01-15 2020-01-15 Polipeptídeos de interleucina-34 (il-34) mutada e usos dos mesmos em terapias

Country Status (13)

Country Link
US (1) US12466866B2 (enrdf_load_html_response)
EP (1) EP3911670B1 (enrdf_load_html_response)
JP (2) JP7645185B2 (enrdf_load_html_response)
KR (1) KR20210121077A (enrdf_load_html_response)
CN (1) CN113508129B (enrdf_load_html_response)
AU (1) AU2020208909B2 (enrdf_load_html_response)
BR (1) BR112021013944A8 (enrdf_load_html_response)
CA (1) CA3126741A1 (enrdf_load_html_response)
ES (1) ES3011707T3 (enrdf_load_html_response)
IL (1) IL284868B2 (enrdf_load_html_response)
MX (1) MX2021008525A (enrdf_load_html_response)
SG (1) SG11202107606VA (enrdf_load_html_response)
WO (1) WO2020148338A1 (enrdf_load_html_response)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020208909B2 (en) * 2019-01-15 2025-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
CN115819614B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于il34的嵌合抗原受体免疫细胞制备及其应用
WO2023246908A1 (zh) * 2022-06-21 2023-12-28 四川大学华西医院 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用
CN115252764A (zh) * 2022-08-09 2022-11-01 南方医科大学 一种白介素在制备治疗急性髓系白血病的药物中的应用
EP4653869A1 (en) * 2024-05-21 2025-11-26 Nantes Université Molecules mimicking interleukin 34 bone regulation activity based on the binding of il-34 to bone morphogenetic proteins, method of screening and pharmaceutical composition

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR520E (fr) 1901-11-13 1903-01-26 Bermont Victor Etienne Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5)
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
EP1026253B2 (en) 1989-03-21 2012-12-19 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
CA2156725A1 (en) 1993-02-22 1994-09-01 Warren S. Pear Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
WO1995028494A1 (en) 1994-04-15 1995-10-26 Targeted Genetics Corporation Gene delivery fusion proteins
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
NZ512553A (en) 1998-12-23 2004-02-27 Pfizer Human monoclonal antibodies to cytotoxic T lymphocyte antigen 4 (CTLA-4)
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP2829609A1 (en) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
JP2004517806A (ja) 2000-07-03 2004-06-17 ブリストル−マイヤーズ　スクイブ　カンパニー 可溶性ｃｔｌａ４分子を使用するリウマチ疾患の処置方法
KR100978836B1 (ko) 2001-10-19 2010-08-30 이소테크니카 인코포레이티드 신규한 시클로스포린 유사체 미세유화액 예비농축물
CN103709250B (zh) 2002-10-17 2016-08-10 根马布股份公司 抗cd20的人单克隆抗体
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
EP2287310B1 (en) * 2004-07-22 2015-05-06 Five Prime Therapeutics, Inc. Compositions and methods using MGD-CSF in disease treatment
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP5252635B2 (ja) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
CN101378773B (zh) 2005-12-20 2013-03-13 布里斯托尔—迈尔斯斯奎布公司 稳定蛋白质制剂
HUE034465T2 (en) 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
SMT202400136T1 (it) 2008-12-09 2024-05-14 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
US8289808B2 (en) 2009-04-16 2012-10-16 Chevron U.S.A., Inc. System and method to estimate compressional to shear velocity (VP/VS) ratio in a region remote from a borehole
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP2504364B1 (en) 2009-11-24 2017-08-09 Medimmune Limited Targeted binding agents against b7-h1
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
SMT201800370T1 (it) 2013-03-15 2018-09-13 Bristol Myers Squibb Co Inibitori di indolamina 2,3-diossigenasi (ido)
LT3041827T (lt) 2013-09-06 2018-07-25 Aurigene Discovery Technologies Limited 1,2,4-oksadiazolo dariniai, kaip imunomoduliatoriai
KR20160081898A (ko) 2013-09-06 2016-07-08 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 유도체
ES2710444T3 (es) * 2014-07-17 2019-04-25 Inst Nat Sante Rech Med Un polipéptido de interleucina 34 aislado para uso en la prevención del rechazo de trasplante y el tratamiento de enfermedades autoinmunitarias
EP3302552A1 (en) * 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
CN106084030B (zh) 2016-04-25 2019-11-08 北京大学 一种提高白细胞介素il-34热稳定性的方法
AU2020208909B2 (en) * 2019-01-15 2025-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy

Also Published As

Publication number Publication date
CN113508129A (zh) 2021-10-15
BR112021013944A2 (enrdf_load_html_response) 2021-11-21
JP2022517029A (ja) 2022-03-03
ES3011707T3 (en) 2025-04-08
EP3911670C0 (en) 2024-12-25
IL284868B1 (en) 2025-05-01
CA3126741A1 (en) 2020-07-23
SG11202107606VA (en) 2021-08-30
AU2020208909A1 (en) 2021-07-29
MX2021008525A (es) 2021-11-12
WO2020148338A1 (en) 2020-07-23
CN113508129B (zh) 2025-02-18
KR20210121077A (ko) 2021-10-07
JP7645185B2 (ja) 2025-03-13
EP3911670B1 (en) 2024-12-25
US20220098264A1 (en) 2022-03-31
US12466866B2 (en) 2025-11-11
EP3911670A1 (en) 2021-11-24
JP2025000723A (ja) 2025-01-07
IL284868A (en) 2021-08-31
AU2020208909B2 (en) 2025-02-20
IL284868B2 (en) 2025-09-01

Similar Documents

Publication Publication Date Title
BR112021013944A8 (pt) Polipeptídeos de interleucina-34 (il-34) mutada e usos dos mesmos em terapias
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CO2023014054A2 (es) Anticuerpos anti-il-2r agonistas y métodos de uso
PE20181338A1 (es) Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
BR112021017621A2 (pt) Composições e métodos de uso compreendendo substâncias com ações de plasticidade neural administradas em dosagens e formulações não psicodélicas/psicotomiméticas
BR112017020750A2 (pt) células t modificadas e métodos de produção e utilização das mesmas
MX2019003445A (es) Proteinas de fusion inmunomoduladoras.
EP4257675A3 (en) Delivery of materials to anucleate cells
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112016023559A2 (pt) mutações de deleção
WO2016022994A3 (en) High affinity pd-1 agents and methods of use
BR112017021869A2 (pt) compostos quinazolina substituídos e métodos de uso dos mesmos
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
CL2024000922A1 (es) Proteínas que se unen a nkg2d, cd16 y baff-r
BR112019002127A2 (pt) proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão
MX2024003363A (es) Derivado de piridina y uso del mismo.
BR112016023688A2 (pt) célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada
CL2020001422A1 (es) Terapias con ligandos de proteína tipo lantionina c 2 y células preparadas con ellas
BR112015019729A2 (pt) composição inibidora da il-1b e uso da mesma
MX2022001866A (es) Muteinas de interleucina-2 para la expansion de celulas t reguladoras.
TWD220400S (zh) 醫療設備之支撐裝置
Saeidi et al. Regulation of CD8+ T-cell cytotoxicity in HIV-1 infection
UY39522A (es) Anticuerpos de cadena pesada que se unen al receptor alfa de folato
Sonon et al. HLA-G,-E and-F regulatory and coding region variability and haplotypes in the Beninese Toffin population sample
BR112018072045A8 (pt) Proteína de fusão, método de preparação da proteína, ácido nucleico, vetor e célula, composição farmacêutica e variante de ccl3ss

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; NANTES UNIVERSITE (FR)